REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

PURPOSE: REOLYSIN (Oncolytics Biotech) consists of a wild-type oncolytic reovirus, which has selective cytotoxicity for tumor cells while sparing normal cells. In a phase I study as a single agent, repeated infusions of reovirus were safe with evidence of antitumor activity. Preclinical studies indi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Comins, Charles, Spicer, James, Protheroe, Andrew, Roulstone, Victoria, Twigger, Katie, White, Christine M., Vile, Richard, Melcher, Alan, Coffey, Matt C., Mettinger, Karl L., Nuovo, Gerard, Cohn, David E., Phelps, Mitch, Harrington, Kevin J., Pandha, Hardev S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3934355/
https://ncbi.nlm.nih.gov/pubmed/20926400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-1233
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados